Centessa Pharmaceuticals (NASDAQ:CNTA) Upgraded to Hold by Zacks Investment Research

Centessa Pharmaceuticals (NASDAQ:CNTAGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports.

According to Zacks, “Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is based in Cambridge, United Kingdom. “

Several other analysts also recently commented on CNTA. Morgan Stanley dropped their price objective on shares of Centessa Pharmaceuticals from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Tuesday, April 5th. The Goldman Sachs Group began coverage on shares of Centessa Pharmaceuticals in a research note on Friday, February 11th. They issued a “neutral” rating and a $12.00 target price for the company.

NASDAQ:CNTA traded down $0.16 during trading hours on Thursday, hitting $4.89. 27,358 shares of the company were exchanged, compared to its average volume of 171,728. The company’s 50 day moving average price is $8.42 and its 200-day moving average price is $9.89. The stock has a market capitalization of $459.76 million and a price-to-earnings ratio of -2.05. The company has a debt-to-equity ratio of 0.15, a current ratio of 25.52 and a quick ratio of 25.52. Centessa Pharmaceuticals has a 52-week low of $4.87 and a 52-week high of $26.90.

Centessa Pharmaceuticals (NASDAQ:CNTAGet Rating) last released its quarterly earnings data on Wednesday, March 30th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.08). On average, equities analysts predict that Centessa Pharmaceuticals will post -3.03 earnings per share for the current year.

In related news, EVP Antoine Yver sold 20,222 shares of the business’s stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $5.42, for a total value of $109,603.24. Following the completion of the transaction, the executive vice president now directly owns 813,675 shares in the company, valued at approximately $4,410,118.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

A number of large investors have recently bought and sold shares of the business. Golden State Equity Partners raised its position in Centessa Pharmaceuticals by 15.1% during the first quarter. Golden State Equity Partners now owns 15,970 shares of the company’s stock worth $143,000 after acquiring an additional 2,100 shares during the period. Bank of America Corp DE acquired a new position in Centessa Pharmaceuticals during the second quarter worth $54,000. JPMorgan Chase & Co. raised its position in Centessa Pharmaceuticals by 146.7% during the fourth quarter. JPMorgan Chase & Co. now owns 4,509 shares of the company’s stock worth $51,000 after acquiring an additional 2,681 shares during the period. Compagnie Lombard Odier SCmA raised its position in Centessa Pharmaceuticals by 111.6% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 5,820 shares of the company’s stock worth $66,000 after acquiring an additional 3,070 shares during the period. Finally, Morgan Stanley acquired a new position in Centessa Pharmaceuticals during the third quarter worth $128,000. Institutional investors own 95.72% of the company’s stock.

Centessa Pharmaceuticals Company Profile (Get Rating)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.

Further Reading

Get a free copy of the Zacks research report on Centessa Pharmaceuticals (CNTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.